((1S)-2,2-difluorocyclopropyl)methyl 4-nitrobenzenesulfonate | 1431534-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((1S)-2,2-difluorocyclopropyl)methyl 4-nitrobenzenesulfonate
• 英文别名: [(1S)-2,2-difluorocyclopropyl]methyl 4-nitrobenzene-1-sulfonate；[(1S)-2,2-difluorocyclopropyl]methyl 4-nitrobenzenesulfonate
• CAS: 1431534-25-6
• 化学式: C₁₀H₉F₂NO₅S
• 分子量: 293.248
• InChiKey: IVBFZUDVXUWEOW-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  97.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-((2S)-1-((2-(4-(benzyloxy)-3-methoxyphenyl)[1,3]oxazolo[4,5-c]pyridin-6-yl)oxy)propan-2-yl)acetamide 、 ((1S)-2,2-difluorocyclopropyl)methyl 4-nitrobenzenesulfonate 以in the same manner as in Step D of Example 68, the title compound was obtained的产率得到N-((2S)-1-((2-(4-(((1S)-2,2-difluorocyclopropyl)methoxy)-3-methoxyphenyl)[1,3]oxazolo[4,5-c]pyridin-6-yl)oxy)propan-2-yl)acetamide
  参考文献：
  名称：

  Bicyclic compound

  摘要：

  本发明提供了一种由式(I)表示的化合物，其中每个符号如规范中所定义，或其盐。

  公开号：

  US09133129B2

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US20180280389A1

  公开（公告）日：2018-10-04

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有CaMKII抑制作用的化合物，预计可用作预防或治疗心脏疾病（特别是儿茶酚胺多形性室性心动过速、术后心房颤动、心力衰竭、致命性心律失常）等的药剂。本发明涉及一种由式（I）表示的化合物： 其中每个符号如规范中定义的，或其盐。
• Substituted amines for treating cardiac diseases
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US10543212B2

  公开（公告）日：2020-01-28

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有 CaMKII 抑制作用的化合物，该化合物有望用作预防或治疗心脏疾病（特别是儿茶酚胺能多形性室性心动过速、术后心房颤动、心力衰竭、致命性心律失常）等的药物。 本发明涉及一种由式（I）代表的化合物： 其中各符号如说明书中所定义，或其盐类。
• BICYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3225618B1

  公开（公告）日：2020-05-06
• SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES
  申请人：Cardurion Pharmaceuticals, LLC

  公开号：US20200230137A1

  公开（公告）日：2020-07-23

  The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
• US9133129B2
  申请人：——

  公开号：US9133129B2

  公开（公告）日：2015-09-15